EQT Private Equity to sell Aldevron to Danaher Corporation for enterprise value of USD 9.6 billion
· Aldevron is a leader in manufacturing high-quality plasmid DNA, mRNA and recombinant proteins · Aldevron’s products empower biotech companies to achieve scientific and medical breakthroughs · During EQT’s ownership, Aldevron has experienced strong organic growth and made significant investments to position itself for further expansion EQT is pleased to announce that the EQT VIII fund (“EQT Private Equity”) has agreed to sell Aldevron to Danaher Corporation for an enterprise value of USD 9.6 billion. EQT Private Equity acquired a majority interest in Aldevron in 2019,